<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-549-89
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1989
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        METRONIDAZOLE INJ 5MG-ML
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METRONIDAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bag
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        18.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ICU Medical Fleet Services, LLC " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ICU Medical Fleet Services, LLC 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HOSPIRA INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XD01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Metronidazole 5 mg/1 ml belongs to a group of medicines known as antibiotics and is used to treat severe infections caused by bacteria that can be killed by the active substance metronidazole.</p><p>&nbsp;</p><p>You may be given Metronidazole 5 mg/1 ml for the treatment of any of the following diseases:</p><p>&nbsp;</p><p>&bull; Infections of the blood, brain, lung, bones, genital tract, pelvic area and stomach</p><p>&nbsp;</p><p>If required, your treatment may be supplemented by other antibiotics. Metronidazole 5 mg/1 ml may be given as a preventive measure prior to operations .</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Metronidazole 5 mg/1 ml</strong></p><p>&bull; if you are allergic (hypersensitive) to metronidazole, other similar substances or any of the other ingredients of Metronidazole 5 mg/1ml.</p><p><strong>&nbsp;</strong></p><p><strong>Take special care with Metronidazole 5 mg/1 ml</strong></p><p>if you have:</p><p>&nbsp;</p><p>&bull; severe liver damage or occurrence of confusion, altered level of consciousness and coma as a result of severe liver damage (hepatic encephalopathy)</p><p>&bull; a disease of brain, spinal cord or nerves.</p><p>&nbsp;</p><p>Therefore, your doctor will very carefully determine whether you should be treated with Metronidazole 5 mg/1 ml.</p><p>&nbsp;</p><p>If convulsive fits or any other nerve affections (e.g. numbness in limbs)become apparent during therapy, your treatment will promptly be revised.</p><p>&nbsp;</p><p>Treatment must be stopped or revised immediately if you get severe diarrhoeawhich may be due to a severe large bowel disease called &ldquo;pseudomembranouscolitis&rdquo; (see also section 4.)</p><p>&nbsp;</p><p>Cases of severe liver toxicity/acute liver failure, including cases with a fatal outcome, in patients with Cockayne syndrome have been reported with product containing metronidazole.</p><p>&nbsp;</p><p>If you are affected by Cockayne syndrome, your doctor should also monitor your liver function frequently while you are being treated with metronidazole and afterwards.</p><p>&nbsp;</p><p>Tell your doctor immediately and stop taking metronidazole if you develop:</p><p>&nbsp;</p><p>&bull; Stomach pain, anorexia, nausea, vomiting, fever, malaise, fatigue, jaundice, dark urine, putty or mastic coloured stools or itching.</p><p>&nbsp;</p><p>As prolonged use of metronidazole may impair blood formation (see section&ldquo;Possible side effects&rdquo;), your blood counts will be monitored during treatment.</p><p>&nbsp;</p><p>If you received this medicine your urine may be darkened.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Taking or using other medicines</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p><strong>Amiodarone (used to treat irregular heartbeat)</strong></p><p>When you receive this medicine, your heart function should be monitored.</p><p>You should see your doctor if you notice any heart function abnormalities, dizziness or fainting.</p><p>&nbsp;</p><p><strong>Barbiturates (the active substance in sleeping pills)</strong></p><p>The duration of action of metronidazole is reduced by phenobarbital; your metronidazole dose may therefore have to be increased.</p><p>&nbsp;</p><p><strong>Birth control pills</strong></p><p>Your birth control pill may be less reliable while you are being given metronidazole.</p><p>&nbsp;</p><p><strong>Busulfan</strong></p><p>Metronidazole should not be given to patients receiving busulfan because in that case toxic effects are more likely to occur.</p><p>&nbsp;</p><p><strong>Carbamazepine (a drug for the treatment of epilepsy)</strong></p><p>This combination also warrants caution because metronidazole may increase the duration of action of carbamazepine.</p><p>&nbsp;</p><p><strong>Cimetidine (a drug for the treatment of stomach disorders)</strong></p><p>Cimetidine may reduce the elimination of metronidazole in isolated cases and subsequently leads to increased serum metronidazole concentrations</p><p>&nbsp;</p><p><strong>Coumarin derivatives (drugs that inhibit blood clotting)</strong></p><p>Metronidazole may enhance the blood clotting inhibition brought about by coumarins. So if you are taking a medicine that inhibits blood clotting (for example warfarin), you may need less of it during treatment with metronidazole.</p><p>&nbsp;</p><p><strong>Cyclosporin (a drug used to suppress undesirable immune responses)</strong></p><p>When cyclosporin is given together with metronidazole, the blood levels of cyclosporin may increase; your doctor will therefore have to adjust your cyclosporin dose as appropriate.</p><p>&nbsp;</p><p><strong>Disulfiram (used in alcohol withdrawal therapy)</strong></p><p>If you are taking disulfiram, you must not be given metronidazole, or disulfiram must be stopped. Combined use of these two drugs may lead to states of confusion up to the point of a serious mental disorder (psychosis).</p><p>&nbsp;</p><p><strong>Drugs containing alcohol</strong></p><p>Please refer to section &lsquo;Using Metronidazole 5 mg/1 ml&rsquo; with food and drink.</p><p>&nbsp;</p><p><strong>Fluorouracil (an anticancer drug)</strong></p><p>The daily dose of Fluorouracil may have to be reduced when giving it together with Metronidazole because metronidazole may lead to an increase of the blood level of Fluorouracil.</p><p>&nbsp;</p><p><strong>Lithium (used to treat mental illness)</strong></p><p>Treatment with lithium preparations requires particularly careful monitoring during treatment with metronidazole, and the dose of the lithium preparation may need to be re-adjusted. Lithium treatment should be tapered or withdrawn before administration of metronidazole.</p><p>&nbsp;</p><p><strong>Mycophenolate mofetil (used for the prevention of rejection reactions after organ transplant)</strong></p><p><strong>&nbsp;</strong></p><p>Its effect may be weakened by metronidazole, so careful monitoring of the effect of the medicine is recommended.</p><p>&nbsp;</p><p><strong>Phenytoin (a drug for the treatment of epilepsy)</strong></p><p>If you are taking phenytoin, your doctor will treat you with metronidazole only with caution because metronidazole may increase the duration of action of phenytoin. On the other hand, phenytoin may reduce the effect of metronidazole.</p><p>&nbsp;</p><p><strong>Tacrolimus (used to suppress unwanted immune reactions)</strong></p><p>The blood levels of this agent and your kidney function should be checked when starting and stopping treatment with metronidazole.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Using Metronidazole 5 mg/1 ml with food and drinkAlcohol</strong></p><p><strong>&nbsp;</strong></p><p>You must not drink any alcoholic beverages or drugs containing alcohol while you are being given metronidazole and up to 48 hours afterwards because this may cause intolerance reactions such as dizziness and vomiting.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>Fertility</strong></p><p>Animal studies only indicate a potential negative influence of metronidazole on the male reproductive system if high doses lying well above the maximum recommended dose for humans were administered.</p><p>&nbsp;</p><p><strong>Contraception in males and females</strong></p><p>If you are taking a birth-control pill, please refer to section &ldquo; Taking or using other medicines&rdquo;.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>If you are pregnant, your doctor will not treat you with metronidazole unless she/he considers this absolutely necessary.</p><p><strong>Breast-feeding</strong></p><p>You should not breast-feed during treatment with metronidazole and not resume nursing for another 2&ndash;3 days thereafter because metronidazole passes into breast milk.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p><strong>&nbsp;</strong></p><p>While taking Metronidazole 5 mg/1 ml you may feel sleepy, dizzy, confused, see or hear things, that are not there (hallucinations), have fits (convulsions) or temporary eyesight problems (such as blurred or double vision). If this happens do not drive or use any machinery or tools.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients of Metronidazole</strong></p><p><strong>5 mg/1 ml</strong></p><p>This medicine contains 14 mmol (or 322 mg) sodium per 100 ml. Your doctor will bear this in mind if you are on a low sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Dosage</strong></p><p>Dosage depends on the nature and severity of your illness, your age and body weight, and your individual response to treatment.</p><p>&nbsp;</p><p>The following dosages are usually prescribed:</p><p>&nbsp;</p><p><strong>Adults and adolescents</strong></p><p><u>Treatment of infections:</u></p><p>&nbsp;</p><p>You may be given 100 ml of the medicine (corresponding to 500 mg ofmetronidazole) every 8 hours.</p><p>&nbsp;</p><p>As an alternative you may receive 200 &ndash; 300 ml (corresponding to 1000&ndash; 1500 mg of metronidazole) as a single dose.</p><p>&nbsp;</p><p>In most cases treatment will take 7 days. Only exceptionally treatment may be continued beyond this time. , although a duration of 10 days should not normally be exceeded.</p><p>&nbsp;</p><p>The dose will be the same for patients with kidney diseases. For patients with liver diseases, lower doses may be required.</p><p>&nbsp;</p><p>If you were treated by artificial kidney your doctor will schedule your infusion after dialysis has been finished. No routine dose adjustment is necessary.</p><p>&nbsp;</p><p>Prevention of infections that might occur after operations When used for prevention of infection in surgery, you may be given 500 mg of the medicine before the operation. The dose will be repeated 8 and 16 hours after the operation.</p><p>&nbsp;</p><p><strong>The Elderly:</strong></p><p>Your doctor will give you this medicine only with special caution.&nbsp;</p><p>&nbsp;</p><p><strong>Children</strong></p><p>Dosing in children is based on body weight (BW).</p><p><strong>&nbsp;</strong></p><p><u>Treatment of infections :</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Age</p></td><td style="vertical-align:top"><p>Dosage</p></td></tr><tr><td style="vertical-align:top"><p>8 weeks to 12 years</p></td><td style="vertical-align:top"><p>20 &ndash; 30 mg of metronidazole per kg BW per</p><p>day as a single dose or divided into 7.5 mg of</p><p>metronidazole per kg BW every 8 hours.</p><p>The daily dose may be increased to 40 mg of</p><p>metronidazole per kg BW if infection is severe.</p></td></tr><tr><td style="vertical-align:top"><p>Under 8 weeks</p></td><td style="vertical-align:top"><p>15 mg of metronidazole per kg BW as a single</p><p>dose daily or divided into 7.5 mg per kg BW every 12 hours.</p></td></tr><tr><td style="vertical-align:top"><p>Newborns of less</p><p>than 40 weeks gestational</p><p>age</p></td><td style="vertical-align:top"><p>As metronidazole may accumulate in these</p><p>patients during the first week of life, the concentration</p><p>of metronidazole in the blood will be checked after a few days of treatment</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Usually treatment will take 7 days.</p><p>&nbsp;</p><p><u>Prevention of infections that might occur after operations:</u></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Age </strong></p></td><td style="vertical-align:top"><p><strong>Dosage</strong></p></td></tr><tr><td style="vertical-align:top"><p>Less than 12 years</p></td><td style="vertical-align:top"><p>20 &ndash; 30 mg of metronidazole per kg BW as a single dose given 1 &ndash; 2 hours before surgery</p></td></tr><tr><td style="vertical-align:top"><p>Newborns of less than 40 weeksgestationalage</p></td><td style="vertical-align:top"><p>10 mg of metronidazole per kg BW as a singledose before surgery</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Method of administration and duration of treatment</strong><strong> </strong></p><p>&nbsp;</p><p>Metronidazole 5 mg/1 ml is administered through a drip directly into a vein (intravenous infusion)</p><p>&nbsp;</p><p>The infusion of one bag usually takes 60 minutes, but it should not be done within less than 20 minutes.</p><p>&nbsp;</p><p>This medicine may be diluted in a suitable vehicle solution for infusion.</p><p>&nbsp;</p><p>The entire metronidazole treatment period is usually 7 days and must not exceed 10 days unless this is absolutely necessary (see also &ldquo;Take special care with Metronidazole 5 mg/1 ml&rdquo;).</p><p>&nbsp;</p><p>If you are concurrently receiving other antibiotics your doctor will give you those medicines separately.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;If you received more Metronidazole 5 mg/1ml than you should : </strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Undesirable effects, as described in the next section, may occur as signs or symptoms of an overdose. Single oral doses of metronidazole, up to 12 g have been reported in suicide attempts and accidental overdoses.</p><p>&nbsp;</p><p>Symptoms were limited to vomiting, ataxia and slight disorientation. There is no known specific antidote or specific treatment of a massive overdose, but metronidazole can be removed by dialysis (that is treatment with artificial kidney) from the body.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Metronidazole 5 mg/1 ml can cause side effects, although not everybody gets them.</p><p>Side effects occur mostly at high doses or with prolonged use.</p><p>The following terms are used to describe the frequency of side effects:</p><p>&nbsp;</p><p>&lsquo;very common&rsquo;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; affects more than 1 of 10 treated patients</p><p>&lsquo;common&rsquo;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; affects 1 to 10 of 100 treated patients</p><p>&lsquo;uncommon&rsquo;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; affects 1 to 10 of 1,000 treated patients</p><p>&lsquo;rare&rsquo;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; affects 1 to 10 of 10,000 treated patients</p><p>&lsquo;very rare&rsquo;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; affects less than 1 of 10,000 treated patients</p><p>&lsquo;not known&rsquo; frequency cannot be estimated from the available data</p><p>&nbsp;</p><p><strong>The following side effects may be serious and, therefore, require</strong></p><p><strong>immediate treatment:</strong></p><p><strong>&nbsp;</strong></p><p><u>Rare:</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Severe persistent diarrhoea (possibly a symptom of a severe bowel infection</p><p>called pseudomembranous colitis, see below)</p><p>&bull;&nbsp;&nbsp;&nbsp; Severe acute hypersensitivity reactions up to allergic shock</p><p>&nbsp;</p><p><u>Very rare:</u></p><p>&bull;&nbsp;&nbsp;&nbsp; White blood cell and platelet counts may decrease during treatment (granulocytopenia, agranulocytosis, pancytopenia, thrombocytopenia).</p><p>&bull;&nbsp;&nbsp;&nbsp; Hepatitis (liver inflammation), jaundice, inflammation of the pancreas (isolated reports)</p><p>&bull;&nbsp;&nbsp;&nbsp; Brain disorders, lack of coordination</p><p>&bull;&nbsp;&nbsp;&nbsp; brain fever not caused by bacterials (aseptic meningitis)</p><p>&bull;&nbsp;&nbsp;&nbsp; Severe inflammatory rash on mucous membranes and the skin with fever, redness and blistering, in extremely rare cases up to skin detachment over extended areas (Stevens-Johnson Syndrome, toxic epidermal necrolysis)</p><p>&nbsp;</p><p><u>Not known:</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Mild to moderate hypersensitivity reactions, swelling of your face, mouth, throat and/or tongue (angioedema).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Gaze spasm, damage or inflammation of the nerves of your eyes</p><p>&bull;&nbsp;&nbsp;&nbsp; Reduced white blood cell, count (leucopenia), severe anaemia (aplastic anaemia)</p><p>&bull;&nbsp;&nbsp;&nbsp; Seizures, nervous disorders such as numbness, pain, furry sensation or tingling in the arms or legs</p><p>&nbsp;</p><p><strong>Other side effects include</strong></p><p><u>Common</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Infections with yeasts (e.g. genital infections)</p><p>&nbsp;</p><p><u>Uncommon</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Darkened urine (due to a metabolite of metronidazole)</p><p>&nbsp;</p><p><u>Rare</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Changes in ECG</p><p>&nbsp;</p><p><u>Very rare:</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Psychotic disorders, including states of confusion, hallucination</p><p>&bull;&nbsp;&nbsp;&nbsp; Headache, dizziness, drowsiness, fever, disturbance of sight and movement, giddiness, speech defects, convulsions</p><p>&bull;&nbsp;&nbsp;&nbsp; Visual disturbances, e.g. double vision, short-sightedness</p><p>&bull;&nbsp;&nbsp;&nbsp; Liver function disorders (such as elevated serum levels of certain enzymes and bilirubin)</p><p>&bull;&nbsp;&nbsp;&nbsp; Allergic skin reactions like itching, hives</p><p>&bull;&nbsp;&nbsp;&nbsp; Joint and muscle pain</p><p>&nbsp;</p><p><u>Not known:</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Sickness, feeling sick, diarrhoea, inflammation of tongue or mouth, belching and bitter taste, metallic taste, pressure above the stomach,furry tongue</p><p>&bull;&nbsp;&nbsp;&nbsp; Difficulty swallowing</p><p>&bull;&nbsp;&nbsp;&nbsp; Anorexia</p><p>&bull;&nbsp;&nbsp;&nbsp; Sad (depressed) mood</p><p>&bull;&nbsp;&nbsp;&nbsp; Sleepiness or sleeplessness, muscle twitching</p><p>&bull;&nbsp;&nbsp;&nbsp; Reddening and itching of the skin (erythema multiforme)</p><p>&bull;&nbsp;&nbsp;&nbsp; Vein wall irritation (to the point of inflamed veins and thrombosis) after intravenous administration, states of weakness, fever</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>To Report side effects</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance and Drug Safety Centre ( NPC )</p><ul><li>Fax: +966 11 205 7662</li><li>Call NPC at 00966 11 2038222, Ext 2317-2356-2340</li><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the reach and sight of children</p><p>&nbsp;</p><p>Store below 25&ordm;C..</p><p>Do not refrigerate.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the bag label.&nbsp; The expiry date refers to the last day of that month.<br /><br />Shelf life (24 months).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is Metronidazole</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are Citric acid Monohydrate, Anhydrous Disodium Hydrogen Phosphate,</p><p>Sodium Chloride and Water for Injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Each 100 mL contains metronidazole 500 mg (5 mg/mL) and sodium chloride 790 mg in water for injection; with dibasic sodium phosphate (anhydrous) 48 mg and citric acid (anhydrous) 23 mg added as buffers. The osmolarity of this solution is 314 mOsmol/liter (calc.). Each 100 mL contains 14 mEq sodium, pH 5.8 (4.5 ― 7.0).
	

HOW SUPPLIED
Metronidazole Injection, USP, sterile, is supplied in 100 mL single dose flexible containers, each containing 500 mg (5 mg/mL) of metronidazole (List 7811).

NDC No.	Product	Fill Volume/Container Size
0409-7811-37	Metronidazole Injection, USP	100 mL
0409-7811-24	Metronidazole Injection, USP	100 mL

	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Hospira Inc,</p><p>Lake Forest, Chicago</p><p>Illinois,</p><p>United states</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p><strong>&nbsp;</strong></p><p>ICU medical Fleet Services LLC,</p><p>3900 Howard Lane</p><p>Austin TX 78728, AUSTIN,</p><p>United states</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2016 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="direction: rtl;">ينتمي ميترونيدازول 5 ملجم/1 مل إلى مجموعة من الأدوية تُعرف باسم المضادات الحيوية، ويُستخدم لعلاج حالات العدوى الشديدة الناتجة عن بكتيريا يمكن القضاء عليها بواسطة المادة الفعالة ميترونيدازول.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">قد يتم إعطاؤك ميترونيدازول 5 ملجم/1 مل لعلاج أي من الأمراض التالية:</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&bull; حالات العدوى التي تصيب الدم، والمخ، والرئتين، والعظام، والجهاز التناسلي، ومنطقة الحوض، والمعدة</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">إذا لزم الأمر، يمكن إضافة مضادات حيوية أخرى إلى علاجك. يمكن إعطاء ميترونيدازول 5 ملجم/1 مل كإجراء وقائي قبل العمليات الجراحية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;"><strong>لا تستخدم ميترونيدازول 5 ملجم/1 مل</strong></p><p style="direction: rtl;">&bull; إذا كنت مصابًا بالحساسية (فرط الحساسية) تجاه ميترونيدازول أو المواد الأخرى المشابهة أو أي من المكونات الأخرى في ميترونيدازول 5 ملجم/1 مل.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>توخ الحذر بشكل خاص عند استخدام ميترونيدازول 5 ملجم/1 مل</strong></p><p style="direction: rtl;">إذا كنت:</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&bull; مصابًا بتلف الكبد الشديد أو إذا تعرضت لحدوث الارتباك وتغير مستوى الوعي وغيبوبة نتيجةً لتلف الكبد الشديد (الاعتلال الدماغي الكبدي)</p><p style="direction: rtl;">&bull; مصابًا بمرض في المخ أو الحبل الشوكي أو الأعصاب.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">لذلك، سيقرر طبيبك بحذر شديد ما إذا كان ينبغي علاجك باستخدام ميترونيدازول 5 ملجم/1 مل أم لا.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">إذا ظهرت نوبات تشنجية أو أي من اعتلالات الأعصاب الأخرى (مثل خدر في الأطراف) أثناء العلاج، فستتم مراجعة علاجك على الفور.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">يجب إيقاف العلاج أو مراجعته فورًا إذا أصبت بإسهال شديد قد يكون بسبب مرض شديد بالأمعاء الغليظة يُدعى &quot;التهاب القولون الغشائي الكاذب&quot; (انظر أيضًا القسم 4).</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">تم الإبلاغ عن حالات إصابة بتسمم الكبد الشديد/فشل الكبد الحاد، بما في ذلك حالات ذات نتائج مميتة، لدى المرضى المصابين بمتلازمة كوكاين عند استخدام منتج يحتوي على ميترونيدازول.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">إذا كنت مصابًا بمتلازمة كوكاين، ينبغي أن يقوم طبيبك أيضًا بمراقبة وظائف كبدك بشكل متكرر أثناء خضوعك للعلاج بميترونيدازول وبعد ذلك.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">أخبر طبيبك فورًا وتوقف عن تناول ميترونيدازول إذا أصبت:</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&bull; بألم في المعدة، أو قهم، أو غثيان، أو قيء، أو حمى، أو توعك، أو إرهاق، أو يرقان، أو تغير لون البول إلى اللون الداكن، أو تغير لون البراز إلى الرمادي الباهت أو الأصفر الباهت، أو الحكة.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">نظرًا لأن الاستخدام المطول لميترونيدازول قد يسبب خللًا في تكوّن الدم (انظر قسم &quot;الآثار الجانبية المحتملة&quot;)، ستتم مراقبة تعدادات دمك أثناء العلاج.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">إذا تلقيت هذا الدواء، فقد يصبح لون بولك داكنًا.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>تناول أو استخدام أدوية أخرى</strong></p><p style="direction: rtl;">يرجى إخبار طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أي أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>أميودارون (يُستخدم لعلاج عدم انتظام ضربات القلب)</strong></p><p style="direction: rtl;">عندما تتلقى هذا الدواء، تنبغي مراقبة وظائف قلبك.</p><p style="direction: rtl;">تنبغي عليك زيارة طبيبك إذا لاحظت أي اضطرابات في وظائف القلب، أو حدوث دوار، أو إغماء.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الباربتيورات (المادة الفعالة في الحبوب المنومة)</strong></p><p style="direction: rtl;">تقل مدة تأثير ميترونيدازول عند تناول فينوباربيتال؛ لذا فقد يلزم زيادة جرعة ميترونيدازول الخاصة بك.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>حبوب منع الحمل</strong></p><p style="direction: rtl;">قد ينخفض تأثير حبوب منع الحمل الخاصة بكِ أثناء إعطائكِ ميترونيدازول.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>بوسلفان</strong></p><p style="direction: rtl;">ينبغي عدم إعطاء ميترونيدازول للمرضى الذين يتلقون بوسلفان لأنه في هذه الحالة تزيد احتمالية حدوث التأثيرات السامة.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>كاربامازيبين (عقار لعلاج الصرع)</strong></p><p style="direction: rtl;">يستلزم هذا العلاج المركب توخي الحذر أيضًا لأن ميترونيدازول قد يزيد مدة تأثير كاربامازيبين.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>سيميتيدين (عقار لعلاج اضطرابات المعدة)</strong></p><p style="direction: rtl;">قد يقلل سيميتيدين معدل إطراح ميترونيدازول في حالات منفصلة مما يؤدي لاحقًا إلى زيادة تركيزات ميترونيدازول في مصل الدم</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>مشتقات الكومارين (عقاقير تثبط تجلط الدم)</strong></p><p style="direction: rtl;">قد يعزز ميترونيدازول من عملية تثبيط تجلط الدم التي تحدثها مركبات الكومارين. لذا، إذا كنت تتناول أحد الأدوية التي تثبط تجلط الدم (على سبيل المثال وارفارين)، فقد تكون بحاجة إلى جرعة أقل من هذا الدواء أثناء العلاج بميترونيدازول.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>سيكلوسبورين (عقار يُستخدم لكبت الاستجابات المناعية غير المرغوب فيها)</strong></p><p style="direction: rtl;">عند إعطاء سيكلوسبورين بالتزامن مع ميترونيدازول، قد تزيد مستويات سيكلوسبورين في الدم؛ ولذلك سيتعين على طبيبك تعديل جرعة سيكلوسبورين الخاصة بك حسبما يقتضي الأمر.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>ديسلفيرام (يُستخدم في علاج انسحاب الكحول)</strong></p><p style="direction: rtl;">إذا كنت تتناول ديسلفيرام، يجب عدم إعطائك ميترونيدازول، أو يجب إيقاف ديسلفيرام. فقد يؤدي استخدام هذين العقارين بالتزامن إلى الإصابة بحالات من الارتباك تصل إلى درجة من الاضطراب العقلي الخطير (الذهان).</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>العقاقير التي تحتوي على الكحول</strong></p><p style="direction: rtl;">يُرجى الرجوع إلى قسم &quot;استخدام ميترونيدازول 5 ملجم/1 مل&quot; مع الطعام والشراب.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>فلورويوراسيل (عقار مضاد للسرطان)</strong></p><p style="direction: rtl;">قد يلزم تقليل الجرعة اليومية لفلورويوراسيل عند إعطائه بالتزامن مع ميترونيدازول لأن ميترونيدازول قد يؤدي إلى ارتفاع مستوى فلورويوراسيل في الدم.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الليثيوم (يُستخدم لعلاج الأمراض العقلية)</strong></p><p style="direction: rtl;">يتطلب العلاج بمستحضرات الليثيوم مراقبة دقيقة بشكل خاص أثناء العلاج بميترونيدازول، وقد تلزم إعادة تعديل جرعة مستحضر الليثيوم. ينبغي إيقاف علاج الليثيوم بشكل تدريجي أو سحبه قبل استعمال ميترونيدازول.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>ميكوفينوليت موفيتيل (يُستخدم لمنع تفاعلات رفض العضو بعد عمليات زراعة الأعضاء)</strong></p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;">قد يتسبب ميترونيدازول في إضعاف تأثير هذا الدواء، لذا يوصى بالمراقبة الدقيقة لتأثيره.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>فينيتوين (عقار لعلاج الصرع)</strong></p><p style="direction: rtl;">إذا كنت تتناول فينيتوين، فلن يعالجك طبيبك بميترونيدازول إلا عند توخي الحذر لأن ميترونيدازول قد يزيد من مدة تأثير فينيتوين. على الجانب الآخر، قد يقلل فينيتوين من تأثير ميترونيدازول.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>تاكروليموس (يُستخدم لكبت التفاعلات المناعية غير المرغوبة)</strong></p><p style="direction: rtl;">ينبغي فحص مستويات هذا العامل في الدم وفحص وظائف كليتك عند بدء العلاج بميترونيدازول وعند إيقافه.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>استخدام ميترونيدازول 5 ملجم/1 مل مع الطعام والشراب الكحوليات</strong></p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;">ينبغي ألا تتناول أي مشروبات كحولية أو عقاقير تحتوي على الكحول عندما يتم إعطاؤك ميترونيدازول ولمدة تصل إلى 48 ساعة بعد ذلك لأن هذا قد يسبب حدوث تفاعلات عدم تحمّل مثل الدوار والقيء.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الحمل والرضاعة الطبيعية</strong></p><p style="direction: rtl;"><strong>الخصوبة</strong></p><p style="direction: rtl;">تشير الدراسات المجراة على الحيوانات فقط إلى وجود تأثير سلبي محتمل لميترونيدازول على الجهاز التناسلي للذكور إذا تم إعطاء جرعات عالية تتجاوز بكثير الحد الأقصى للجرعة الموصى بها للبشر.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>وسائل منع الحمل بالنسبة للذكور والإناث</strong></p><p style="direction: rtl;">إذا كنتِ تتناولين حبوب منع الحمل، يُرجى الرجوع إلى قسم &quot;تناول أو استخدام أدوية أخرى&quot;.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الحمل</strong></p><p style="direction: rtl;">إذا كنتِ حاملًا، فلن يقوم طبيبكِ بعلاجكِ بميترونيدازول إلا إذا كان يرى هذا أمرًا ضروريًا للغاية.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الرضاعة الطبيعية</strong></p><p style="direction: rtl;">ينبغي ألا تقومي بالرضاعة الطبيعية أثناء العلاج بميترونيدازول وألا تعاودي الإرضاع إلا بعد مرور يومين إلى 3 أيام أخرى من انتهاء العلاج لأن ميترونيدازول يمر في حليب الثدي.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>القيادة واستخدام الآلات</strong></p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;">أثناء استخدام ميترونيدازول 5 ملجم/1 مل، قد تشعر بالنعاس، أو الدوار، أو الارتباك، أو ترى أو تسمع أشياء ليس لها وجود (هلاوس)، أو تصاب بنوبات (اختلاجات)، أو بمشكلات مؤقتة في الرؤية (مثل تغيم الرؤية أو الرؤية المزدوجة). إذا حدث ذلك، فامتنع عن القيادة ولا تستخدم أي آلات أو أدوات.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>معلومات مهمة عن بعض مكونات ميترونيدازول</strong><strong> </strong><strong>5 ملجم/1 مل</strong></p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;">يحتوي هذا الدواء على 14 مليمول (أو 322 ملجم) من الصوديوم لكل 100 مل. سيضع طبيبك هذا في اعتباره إذا كنت متبعًا لحمية غذائية قليلة الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;"><strong>الجرعة</strong></p><p style="direction: rtl;">تعتمد الجرعة على طبيعة مرضك وشدته، وعمرك ووزن جسمك، واستجابتك الفردية للعلاج.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">غالبا ما يتم وصف الجرعات التالية:</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>البالغون والمراهقون</strong></p><p style="direction: rtl;"><u>علاج حالات العدوى:</u></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">قد يتم إعطاؤك 100 مل من الدواء (بما يقابل 500 ملجم من ميترونيدازول) كل 8 ساعات.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">وكبديل، يمكن أن تتلقى 200 &ndash; 300 مل (بما يقابل 1000 &ndash; 1500 ملجم من ميترونيدازول) كجرعة فردية.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">في معظم الحالات سيستغرق العلاج 7 أيام. وبشكل استثنائي فقط يمكن أن يستمر العلاج ليتجاوز تلك الفترة، على الرغم من أنه لا ينبغي عادة أن تتجاوز فترة العلاج 10 أيام.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">ستُستخدم نفس الجرعة للمرضى المصابين بأمراض الكلى. للمرضى المصابين بأمراض الكبد، قد يلزم استخدام جرعات أقل.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">إذا تم علاجك عن طريق الكلى الصناعية، فسيقوم طبيبك بتحديد موعد جلسة التسريب الخاصة بك لتكون بعد انتهاء الديلزة. لا يلزم إجراء أي تعديل روتيني للجرعة.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">الوقاية من حالات العدوى التي قد تحدث بعد العمليات الجراحية. عند استخدام الدواء للوقاية من العدوى في الجراحة، قد يتم إعطاؤك 500 ملجم من الدواء قبل العملية الجراحية. ستُكرر الجرعة بعد العملية الجراحية بـ8 ساعات و16 ساعة.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>المسنون:</strong></p><p style="direction: rtl;">لن يعطيك طبيبك هذا الدواء إلا بعد توخي الحذر بشكل خاص.&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الأطفال</strong></p><p style="direction: rtl;">تتحدد الجرعات في الأطفال بناءً على وزن الجسم (BW).</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><u>علاج حالات العدوى:</u></p><p style="direction: rtl;">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="direction:rtl"><tbody><tr><td style="vertical-align:top"><p>العمر</p></td><td style="vertical-align:top"><p>الجرعة</p></td></tr><tr><td style="vertical-align:top"><p>من 8 أسابيع إلى 12 عامًا</p></td><td style="vertical-align:top"><p>20 &ndash; 30 ملجم من ميترونيدازول لكل كلجم من وزن الجسم في</p><p>اليوم كجرعة فردية أو تقسيم الجرعة إلى 7.5 ملجم من</p><p>ميترونيدازول لكل كلجم من وزن الجسم كل 8 ساعات.</p><p>يمكن زيادة الجرعة اليومية إلى 40 ملجم من</p><p>ميترونيدازول لكل كلجم من وزن الجسم إذا كانت العدوى شديدة.</p></td></tr><tr><td style="vertical-align:top"><p>أقل من 8 أسابيع</p></td><td style="vertical-align:top"><p>15 ملجم من ميترونيدازول لكل كلجم من وزن الجسم كجرعة</p><p>فردية يوميًا أو تقسيم الجرعة إلى 7.5 ملجم لكل كلجم من وزن الجسم كل 12 ساعة.</p></td></tr><tr><td style="vertical-align:top"><p>حديثو الولادة الذين يقل</p><p>عمرهم الحملي عن 40</p><p>أسبوعًا</p></td><td style="vertical-align:top"><p>نظرًا لأن ميترونيدازول قد يتراكم في هؤلاء</p><p>المرضى خلال الأسبوع الأول من حياتهم، فسيتم فحص تركيزات</p><p>ميترونيدازول في الدم بعد مرور بضعة أيام من العلاج</p></td></tr></tbody></table><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">سيستغرق العلاج غالبًا 7 أيام.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><u>الوقاية من حالات العدوى التي قد تحدث بعد العمليات الجراحية:</u></p><p style="direction: rtl;">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="direction:rtl"><tbody><tr><td style="vertical-align:top"><p><strong>العمر </strong></p></td><td style="vertical-align:top"><p><strong>الجرعة</strong></p></td></tr><tr><td style="vertical-align:top"><p>أقل من 12 عامًا</p></td><td style="vertical-align:top"><p>20 &ndash; 30 ملجم من ميترونيدازول لكل كلجم من وزن الجسم كجرعة فردية قبل الجراحة بساعة إلى ساعتين</p></td></tr><tr><td style="vertical-align:top"><p>حديثو الولادة الذين يقل عمرهم الحملي عن 40 أسبوعًا</p></td><td style="vertical-align:top"><p>10 ملجم من ميترونيدازول لكل كلجم من وزن الجسم كجرعة فردية قبل الجراحة</p></td></tr></tbody></table><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>طريقة الاستعمال ومدة العلاج </strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">يُستعمل ميترونيدازول 5 ملجم/1 مل عن طريق التنقيط مباشرة في أحد الأوردة (التسريب عن طريق الوريد)</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">غالبًا ما يستغرق تسريب عبوة واحدة 60 دقيقة، ولكن ينبغي ألا يتم إجراء التسريب خلال ما يقل عن 20 دقيقة.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">يمكن تخفيف هذا الدواء في محلول وسيط مناسب مخصص للتسريب.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">غالبًا ما تستغرق فترة العلاج بميترونيدازول بالكامل 7 أيام ويجب ألا تتعدى 10 أيام إلا إذا كان ذلك ضروريًا للغاية (انظر أيضًا قسم &quot;توخ الحذر بشكل خاص عند استخدام ميترونيدازول 5 ملجم/1 مل&quot;).</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">إذا كنت تتلقى مضادات حيوية أخرى بالتزامن، فسيعطيك طبيبك تلك الأدوية بشكل منفصل.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>&nbsp;إذا تلقيت جرعة من ميترونيدازول 5 ملجم/1 مل أكبر مما ينبغي: </strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">قد تحدث آثار غير مرغوب فيها، كما هو موضح في القسم التالي، كعلامات أو أعراض لتناول جرعة مفرطة. تم الإبلاغ عن تناول جرعات فردية من ميترونيدازول عن طريق الفم، وصلت إلى 12 جم، في محاولات الانتحار وحالات الجرعات المفرطة المتلقاة عن طريق الخطأ.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">اقتصرت الأعراض على القيء، والترنح، والتوهان الطفيف. لا يوجد ترياق محدد أو علاج محدد معروفان للجرعة المفرطة الكبيرة، ولكن يمكن إزالة ميترونيدازول من الجسم عن طريق الديلزة (وهي العلاج باستخدام الكلى الصناعية).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">كما هو الحال مع جميع الأدوية، يمكن أن يسبب ميترونيدازول 5 ملجم/1 مل آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p style="direction: rtl;">تحدث الآثار الجانبية غالبًا في الجرعات العالية أو مع الاستخدام المطول.</p><p style="direction: rtl;">تستخدم المصطلحات التالية لوصف معدل تكرار الآثار الجانبية:</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&quot;شائعة جدًا&quot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;تصيب أكثر من شخص واحد من كل 10 مرضى معالجين</p><p style="direction: rtl;">&quot;شائعة&quot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصيب من شخص واحد إلى 10 أشخاص من كل 100 مريض معالج</p><p style="direction: rtl;">&quot;غير شائعة&quot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;تصيب من شخص واحد إلى 10 أشخاص من كل 1000 مريض معالج</p><p style="direction: rtl;">&quot;نادرة&quot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تصيب من شخص واحد إلى 10 أشخاص من كل 10000 مريض معالج</p><p style="direction: rtl;">&quot;نادرة جدًا&quot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصيب أقل من شخص واحد من كل 10000 مريض معالج</p><p style="direction: rtl;">&quot;غير معروفة&quot; لا يمكن تقدير معدل التكرار من البيانات المتاحة</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>قد تكون الآثار الجانبية التالية خطيرة، ولذلك فهي تتطلب</strong></p><p style="direction: rtl;"><strong>العلاج الفوري:</strong></p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;"><u>نادرة:</u></p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; الإسهال الشديد المستمر (من المحتمل أن يكون أحد أعراض عدوى شديدة بالأمعاء</p><p style="direction: rtl;">تسمى التهاب القولون الغشائي الكاذب، انظر أدناه)</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; تفاعلات فرط الحساسية الشديدة الحادة بما يصل إلى صدمة حساسية</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><u>نادرة جدًا:</u></p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; قد ينخفض تعداد خلايا الدم البيضاء والصفائح الدموية أثناء العلاج (نقص المحببات، ندرة المحببات، قلة الكريات الشاملة، قلة الصفيحات).</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; التهاب الكبد الوبائي (التهاب الكبد)، اليرقان، التهاب البنكرياس (تقارير منفصلة)</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; اضطرابات المخ، غياب التنسيق في حركة الجسم</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; حمى المخ غير الناتجة عن حالات العدوى البكتيرية (التهاب السحايا العقيم)</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; طفح جلدي التهابي شديد على الأغشية المخاطية والجلد، مصحوب بحمى واحمرار وتبثر، وفي الحالات النادرة جدًا قد يصل الأمر إلى انفصال الجلد على نطاق مناطق ممتدة (متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية التسممي)</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><u>غير معروفة:</u></p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; تفاعلات فرط الحساسية الخفيفة إلى المتوسطة، تورم وجهك و/أو فمك و/أو حلقك و/أو لسانك (التورم الوعائي).</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; تشنج بحركة العين، تلف أو التهاب أعصاب عينيك</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم البيضاء (نقص الكريات البيض)، فقر الدم الشديد (فقر الدم اللاتنسجي)</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; النوبات، اضطرابات عصبية مثل الخدر، أو الألم، أو الإحساس بوجود شعر أو تنميل في الذراعين أو الساقين</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>تتضمن الآثار الجانبية الأخرى</strong></p><p style="direction: rtl;"><u>شائعة</u></p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; حالات العدوى بالخمائر (مثل حالات العدوى التي تصيب المناطق التناسلية)</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><u>غير شائعة</u></p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; بول داكن (بسبب أحد نواتج أيض ميترونيدازول)</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><u>نادرة</u></p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; تغيرات في رسم القلب</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><u>نادرة جدًا:</u></p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; اضطرابات ذهانية، بما في ذلك حالات الارتباك، الهلاوس</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; الصداع، الدوار، النعاس، الحمى، اضطراب الرؤية والحركة، الدوخة، مشكلات التخاطب، الاختلاجات</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; اضطرابات الرؤية، مثل الرؤية المزدوجة، قصر النظر</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; اضطرابات وظائف الكبد (مثل ارتفاع مستويات إنزيمات معينة ومستوى البيليروبين في مصل الدم)</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; تفاعلات حساسية جلدية مثل الحكة، الشرى</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; ألم في المفاصل والعضلات</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><u>غير معروفة:</u></p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; الإعياء، الغثيان، الإسهال، التهاب اللسان أو الفم، التجشؤ والمذاق المر، المذاق المعدني، ضغط أعلى المعدة، اللسان المشعر</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; صعوبة البلع</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; القهم</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; الشعور بحالة مزاجية حزينة (الاكتئاب)</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; النعاس أو الأرق، ارتعاش العضلات</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; احمرار الجلد والشعور بحكة فيه (الاحمرار الجلدي عديد الأشكال)</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp; تهيج جدار الأوردة (إلى درجة الإصابة بالتهاب الأوردة والخثار) بعد الاستعمال عن طريق الوريد، حالة من الضعف، الحمى</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي بشأنها. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p style="direction: rtl;">للإبلاغ عن الآثار الجانبية</p><p style="direction: rtl;">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><table border="1" cellspacing="0" cellpadding="0" style="direction:rtl"><tbody><tr><td style="vertical-align:top"><p>المركز الوطني للتيقظ والسلامة الدوائية (NPC)</p><ul><li>الفاكس: 00966112057662</li><li>اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على الرقم: 00966112038222، تحويلة: 2317-2356-2340</li><li>الرقم المجاني: 19999</li><li>البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li>الموقع الإلكتروني: <em>&nbsp;</em>https://ade.sfda.gov.sa</li></ul><p>&nbsp;</p></td></tr></tbody></table><p style="direction: rtl;">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">احتفظ بهذا الدواء بعيدًا عن متناول ومرأى الأطفال</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">يخزَّن في درجة حرارة أقل من 25 درجة مئوية.</p><p style="direction: rtl;">لا يُحفظ في الثلاجة.</p><p style="direction: rtl;">تاريخ الصلاحية: 24 شهرا</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصقالعبوة البلاستيكية .&nbsp; يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>محتويات ميترونيدازول 5 ملجم/1 مل </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي ميترونيدازول</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي أحادي هيدرات حمض السيتريك، وفوسفات الهيدروجين ثنائي الصوديوم اللا مائي،</p><p>وكلوريد الصوديوم، وماء للحقن</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            	يحتوي كل 100 مل على 500 ملجم ميترونيدازول (5 ملجم/مل) و790 ملجم كلوريد الصوديوم في ماء للحقن؛ مع 48 ملجم فوسفات الصوديوم ثنائي القاعدية (اللا مائي) و23 ملجم حمض الستريك (اللا مائي) مضافين كعاملي تثبيت. أسمولية هذا المحلول تبلغ 314 ملي أسمول/لتر (محسوبة). يحتوي كل 100 مل على 14 مل مكافئ من الصوديوم، بدرجة حموضة 5.8 (4.5 ― 7.0).
	

كيفية التوريد
يتم توريد ميترونيدازول المعقم المخصص للحقن، وفقًا لدستور الأدوية الأمريكي، في حاويات مرنة سعة 100 مل مخصصة لجرعة فردية، تحتوي كل منها على 500 ملجم (5 ملجم/مل) من ميترونيدازول (القائمة 7811).

رقم NDC	المنتج	حجم المنتج المملوء/حجم الحاوية
0409-7811-37	ميترونيدازول مخصص للحقن، وفقًا لدستور الأدوية الأمريكي	100 مل
0409-7811-24	ميترونيدازول مخصص للحقن، وفقًا لدستور الأدوية الأمريكي	100 مل


        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;"><strong>&nbsp;مالك تصريح التسويق </strong></p><p style="direction: rtl;">Hospira Inc,</p><p style="direction: rtl;">Lake Forest, Chicago</p><p style="direction: rtl;">&nbsp;Illinois</p><p style="direction: rtl;">United states، الولايات المتحدة</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الجهة المصنعة:</strong></p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;">ICU medical Fleet Services LLC,</p><p style="direction: rtl;">3900 Howard Lane</p><p style="direction: rtl;">Austin TX 78728, AUSTIN,</p><p style="direction: rtl;">United states، الولايات المتحدة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر/تشرين الثاني 2016 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Metronidazole 5mg/ml Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 100 mL contains metronidazole 500 mg (5 mg/mL) and sodium chloride 790 mg in water for injection; with dibasic sodium phosphate (anhydrous) 48 mg and citric acid (anhydrous) 23 mg added as buffers. The osmolarity of this solution is 314 mOsmol/liter (calc.). Each 100 mL contains 14 mEq sodium, pH 5.8 (4.5 ― 7.0).

For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metronidazole 5mg/1ml Solution for Infusion is indicated in adults and&nbsp;children for the prophylaxis and treatment of infections in which susceptible&nbsp;anaerobic micro-organisms have been identified or are suspected to be the cause (see</p><p>sections 4.4 and 5.1).</p><p>1. The prevention of post-operative infections where anaerobic bacteria are expected&nbsp;to be causative pathogens</p><p>2. The treatment of peritonitis, brain abscess, necrotising pneumonia, osteomyelitis,&nbsp;puerperal sepsis, pelvic abscess, and post-operative wound infections from which&nbsp;pathogenic anaerobes have been isolated.</p><p>&nbsp;</p><p>Treatment of patients with bacteraemia that occurs in association with, or is suspected&nbsp;to be associated with, any of the infections listed above.</p><p>Consideration should be given to official guidance on the appropriate use of&nbsp;antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dosage is adjusted according to the patient&rsquo;s individual response to therapy, her/his age and body weight and according to nature and severity of the disease.</p><p>&nbsp;</p><p>The following dosage guidelines should be followed :</p><p>&nbsp;</p><p>Adults and adolescents:</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Treatment of anaerobic infections</u></p><p>500 mg (100 ml) every 8 hours. Alternatively 1000 mg &ndash; 1500 mg may be given daily as a single dose.</p><p>The duration of therapy is dependent on the effect of the treatment. In most cases a treatment course of 7 days will be sufficient. If clinically indicated, treatment may be continued beyond this time although a duration of 10 days should not normally be exceeded. (See also section 4.4.)</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Prophylaxis against post-operative infection caused by anaerobic bacteria:</u></p><p>500 mg, with administration completed approximately one hour before surgery. The dose is repeated after 8 and 16 hours.</p><p>&nbsp;</p><p><em>The Elderly:</em></p><p>Caution is advised in the elderly, particularly at high doses, although there is limited</p><p>information available on modification of dosage.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Paediatric population:</em></p><p>&nbsp;</p><p><u>Treatment of anaerobic infections</u></p><ul><li>Children &gt; 8 weeks to 12 years of age:</li></ul><p>The usual daily dose is 20 &ndash; 30 mg per kg BW per day as a single dose or divided into 7.5 mg per kg BW every 8 hours. The daily dose maybe increased to 40 mg per kg BW, depending on the severity of the infection.</p><p><u>&nbsp;</u></p><p>&nbsp;</p><p>&nbsp;</p><ul><li>Neonates and infants &lt; 8 weeks of age:</li></ul><p>15 mg per kg BW as a single dose daily or divided into 7.5 mg per kg BW every 12 hours.</p><p>&nbsp;</p><ul><li>In newborns with a gestational age &lt; 40 weeks, accumulation of metronidazole can occur during the first week of life; therefore the concentrations of metronidazole in serum should</li></ul><p>preferably be monitored after a few days therapy.</p><p>&nbsp;</p><p>Duration of treatment is usually 7 days.</p><p>&nbsp;</p><p><u>Prophylaxis against postoperative infections caused by anaerobic bacteria:</u></p><p><u>&nbsp;</u></p><ul><li>Children &lt; 12 years:</li></ul><p>20 &ndash; 30 mg/kg BW as a single dose given 1 &ndash; 2 hours before surgery</p><p>&nbsp;</p><ul><li>Newborns with a gestation age &lt;40 weeks:</li></ul><p>10 mg/kg BW as a single dose before surgery</p><p>&nbsp;</p><p><em>Patients with renal insufficiency</em></p><p>Limited data are available in this population. These data do not indicate the</p><p>need for dose reduction (see section 5.2.)</p><p>In patients undergoing haemodialysis the conventional dose of metronidazole should be scheduled after haemodialysis on dialysis days to compensate the removal of metronidazole during the procedure. No routine dose adjustment is necessary in patients with renal failure undergoing intermittent peritoneal dialysis (IDP) or continuous ambulatory peritoneal dialysis (CAPD).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Patients with hepatic insufficiency</em></p><p>As serum half-life is prolonged and plasma clearance is delayed in severe hepatic insufficiency, patients with severe liver disease will require lower doses (see section 5.2).</p><p>&nbsp;</p><p>In patients with hepatic encephalopathy, the daily dosage should be reduced to one third and may be administered once daily (see section 4.4).</p><p>&nbsp;</p><p><em>Method of administration</em></p><p>Intravenous use.</p><p>&nbsp;</p><p>The contents of one bag are to be infused slowly i.v., i.e. 100 ml max. over not less than 20 minutes, but normally over one hour.</p><p>Metronidazole 5mg/1ml Solution for Infusion can also be diluted before administration, adding the medicinal product to an i.v. vehicle solution such as 0.9 % sodium chloride or 5 % glucose infusion solution. Concurrently prescribed antibiotics are to be administered separately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to metronidazole or other nitroimidazole derivatives or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Patients with hepatic impairment</u></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>In patients with severe liver damage metronidazole should only be used if its expected benefits clearly outweigh potential hazards.</p><p>&nbsp;</p><p>Metronidazole is mainly metabolised by hepatic oxidation. Substantial impairment of metronidazole clearance may occur in the presence of advanced hepatic insufficiency. Significant cumulation may occur in patients with hepatic encephalopathy and the resulting high plasma concentrations of metronidazole may contribute to the symptoms of the encephalopathy. Metronidazole should therefore be administered with caution to patients with hepatic encephalopathy. (see section 4.2).</p><p>&nbsp;</p><p>Due to the risk of aggravation, metronidazole should also be used in patients with active or chronic severe peripheral and central nervous system diseases only if its expected benefits clearly outweigh potential hazards.</p><p>&nbsp;</p><p>Convulsive seizures, myoclonus and peripheral neuropathy, the latter mainly characterized by numbness or paresthesia of an extremity, have been reported in patients treated with metronidazole. The appearance of abnormal neurological signs demands the prompt evaluation of the benefit/risk ratio of the continuation of therapy.</p><p>&nbsp;</p><p>&nbsp;</p><p>Patients should be advised not to take alcohol during Metronidazole therapy and at least 48 hours afterwards because of a disulfram-like effect (flushing, vomiting,tachycardia).</p><p>&nbsp;</p><p>In the case of severe hypersensitivity reactions (e.g. anaphylactic shock), treatment with Metronidazole 5mg/1ml Solution for Infusion must be discontinued immediately and established emergency treatment must be initiated by qualified healthcare professionals.</p><p>&nbsp;</p><p>Severe persistent diarrhoea occurring during treatment or during the subsequent weeks may be due to pseudomembranous colitis (in most cases caused by <em>clostridium</em> <em>difficile</em>), see section 4.8. This intestinal disease, precipitated by the antibiotic treatment, may be life-threatening and requires immediate appropriate treatment. Anti-peristaltic medicinal products must not be given.</p><p>&nbsp;</p><p>The duration of therapy with metronidazole or drugs containing other nitroimidazoles should not exceed 10 days. Only in specific elective cases and if definitely needed, the treatment period may be extended, accompanied by appropriate clinical and laboratory monitoring. Repeat therapy should be restricted as much as possible and to specific elective cases only. These restrictions must be observed strictly because the possibility of metronidazole developing mutagenic activity cannot be safely excluded and because in animal experiments an increase of the incidence of certain tumors has been noted.</p><p>&nbsp;</p><p>Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use. In this population, metronidazole should therefore be used after careful benefit-risk assessment and only if no alternative treatment is available. Liver function tests must be performed just prior to the start of therapy, throughout and after end of treatment until liver function is within normal ranges, or until the baseline values are reached. If the liver function tests become markedly elevated during treatment, the drug should be discontinued.</p><p>&nbsp;</p><p>Patients with Cockayne syndrome should be advised to immediately report any symptoms of potential liver injury to their physician and stop taking metronidazole.</p><p>&nbsp;</p><p>Prolonged therapy with metronidazole may be associated with bone marrow depression, leading to an impairment of haematopoiesis. Manifestations see section 4.8. Blood cell counts should be carefully monitored during prolonged therapy.</p><p>&nbsp;</p><p>This medicinal product contains 14 mmol (or 322 mg) sodium per 100 ml. This is to be taken into consideration for patients on a controlled sodium diet.</p><p>&nbsp;</p><p><u>Interference with laboratory tests</u></p><p><u>&nbsp;</u></p><p>Metronidazole interferes with the enzymatic-spectrophotometric determination of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), triglycerides and glucose hexokinase resulting in decreased values (possibly down to zero).</p><p>&nbsp;</p><p>Metronidazole has a high absorbance at the wavelength at which nicotinamide-adenine dinucleotide (NADH) is determined. Therefore elevated liver enzyme concentrations may be masked by metronidazole when measured by continuous-flow methods based on endpoint decrease in reduced NADH. Unusually low liver enzyme concentrations, including zero values, have been reported.</p><p>&nbsp;</p><p>Patients should be warned that Metronidazole may darken urine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interactions with other medicinal products</p><p>&nbsp;</p><p><em>Amiodarone</em></p><p>QT interval prolongation and torsade de pointes have been reported with the coadministration of metronidazole and amiodarone. It may be appropriate to monitor QT interval on the ECG if amiodarone is used in combination with metronidazole.</p><p>Patients treated on an outpatient basis should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.</p><p>&nbsp;</p><p><em>Barbiturates</em></p><p>Phenobarbital may increase the hepatic metabolism of metronidazole, reducing its plasma half life to 3 hours.</p><p>&nbsp;</p><p><em>Busulfan</em></p><p>Coadministration with metronidazole may significantly increase the plasma concentrations of busulfan. The mechanism of interaction has not been described. Due to the potential for severe toxicity and mortality associated with elevated busulfan plasma levels, concomitant use with metronidazole should be avoided.</p><p>&nbsp;</p><p><em>Carbamazepine</em></p><p>Metronidazole may inhibit the metabolism of carbamazepine and raise the plasma concentrations as a consequence.</p><p>&nbsp;</p><p><em>Cimetidine</em></p><p>Concurrently administered cimetidine may reduce the elimination of metronidazole in isolated cases and subsequently lead to increased metronidazole concentrations in serum.</p><p>&nbsp;</p><p><em>Contraceptive drugs</em></p><p>Some antibiotics can, in some exceptional cases, decrease the effect of contraceptive pills by interfering with the bacterial hydrolysis of steroid conjugates in the intestine and hereby reduce the re-absorption of unconjugated steroid. Therefore the plasma levels of the active steroid decrease. This unusual interaction can occur in women with a high excretion of steroid conjugates through the bile. There are case reports of</p><p>oral contraceptive failure in association with different antibiotics, e.g. ampicillin, amoxicillin, tetracyclines and also metronidazole.</p><p>&nbsp;</p><p><em>Coumarin derivatives</em></p><p>Concomitant treatment with metronidazole may potentiate the anticoagulant effect of these and increase the risk for bleeding as a consequence of decreased hepatic degradation. Dose adjustment of the anticoagulant can be necessary.</p><p>&nbsp;</p><p><em>Ciclosporine</em></p><p>During simultaneous therapy with cyclosporine and metronidazole there is a risk for increased serum concentrations of cyclosporine. Frequent monitoring of cyclosporine and creatinine is required.</p><p>&nbsp;</p><p><em>Disulfiram</em></p><p>Simultaneous administration of disulfiram may cause states of confusion or even psychotic reactions. Combination of both agents must be avoided.</p><p>&nbsp;</p><p><em>Fluorouracil</em></p><p>Metronidazole inhibits the metabolism of concurrently administered fluorouracil, i.e. the plasma concentration of fluorouracil is increased.</p><p>&nbsp;</p><p><em>Lithium</em></p><p>Caution is to be exercised when metronidazole is administered simultaneously with lithium salts, because under metronidazole therapy raised serum concentrations of lithium have been observed. Lithium treatment should be tapered or withdrawn before administering metronidazole. Plasma concentrations of lithium, creatinine and electrolytes should be monitored in patients under treatment with lithium while they receive metronidazole.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Mycophenolat mofetil</em></p><p>Substances that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.</p><p>&nbsp;</p><p><em>Phenytoin</em></p><p>Metronidazole inhibits the metabolism of concurrently administered phenytoin, i.e. the plasma concentration of phenytoin is increased. On the other hand, the efficacy of metronidazole is reduced when phenytoin is administered concurrently.</p><p>&nbsp;</p><p><em>Tacrolimus</em></p><p>Coadministration with metronidazole may increase the blood concentrations of tacrolimus. The proposed mechanism is inhibition of hepatic tacrolimus metabolism via CYP 3A4. Tacrolimus blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of metronidazole therapy in patients who are stabilized on their tacrolimus regimen.</p><p>&nbsp;</p><p>Other forms of interaction</p><p><em>Alcohol</em></p><p><em>&nbsp;</em></p><p>Disulfiram-like effect. Alcoholic beverages and drugs containing alcohol should be avoided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><em>Fertility</em></p><p>Animal studies only indicate a potential negative influence of metronidazole on the male reproductive system if high doses lying well above the maximum recommended dose for humans were administered.</p><p>&nbsp;</p><p><em>Contraception in males and females</em></p><p><em>&nbsp;</em></p><p>&ndash; See section 4.5 &lsquo;contraceptive drugs&rsquo;</p><p>&nbsp;</p><p><em>Pregnancy</em></p><p>The safety of the use of metronidazole during pregnancy has not sufficiently been demonstrated. In particular, reports on the use during early pregnancy are contradictory. Some studies indicated an increased rate of malformations. In animal studies with metronidazole no teratogenicity was observed (see section 5.3).</p><p>During the first trimester, Metronidazole&nbsp; Solution for Infusion should only be used to treat severe life-threatening infections, if there is no safer alternative. During the second and third trimester, Metronidazole Solution for Infusion may also be used to treat other infections if its expected benefits clearly outweigh any possible risk.</p><p>&nbsp;</p><p><em>Breast-feeding</em></p><p>Since metronidazole is secreted into breast milk, nursing should be stopped during therapy. Also after the end of the therapy with metronidazole, nursing should not be resumed before another 2 &ndash; 3 days because of the prolonged half-life period of metronidazole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Patients should be warned about the potential for drowsiness, dizziness, confusion, hallucinations, convulsions or transient visual disorders, and are advised not to drive or operate machinery if these symptoms occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects are mainly associated with prolonged use or high doses. The most commonly observed effects include nausea, abnormal taste sensations and the risk of neuropathy in case of long term treatment.</p><p>&nbsp;</p><p>In the following listing, for the description of the frequencies of undesirable effects the following terms are used:</p><p>&nbsp;</p><p>Very common:&ge; 1/10</p><p>Common :&ge; 1/100 to &lt; 1/10</p><p>Uncommon :&ge; 1/1,000 to &lt; 1/100</p><p>Rare :&ge; 1/10,000 to &lt; 1/1,000</p><p>Very rare :&lt; 1/10,000</p><p>Not known :(Frequency cannot be estimated from the available data)</p><p>&nbsp;</p><p><em>Infections and infestations</em></p><p><u>Common:</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Superinfections with candida (e.g. genital infections)</p><p><u>Rare:</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pseudomembranous colitis,</p><p>&nbsp;</p><p><em>Blood and lymphatic system disorders</em></p><p><u>Very rare:</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; granulocytopenia, agranulocytosis, pancytopenia and thrombocytopenia</p><p><u>Not known:</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leucopenia, aplastic anaemia</p><p>&nbsp;</p><p><em>Immune system disorders</em></p><p><u>Rare:</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe acute systemic hypersensitivity reactions: anaphylaxis, up to anaphy lactic shock.</p><p><u>Not known</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angioedema.</p><p>&nbsp;</p><p><em>Metabolism and nutrition disorders</em></p><p><u>Not known</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anorexia</p><p>&nbsp;</p><p><em>Psychiatric disorders</em></p><p><u>Very rare</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psychotic disorders, including states of confusion, hallucination</p><p><u>Not known</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression</p><p>&nbsp;</p><p><em>Nervous system disorders</em></p><p><u>Very rare</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Encephalopathy, headache, fever, drowsiness, and dizziness, disturbances in sight and movement, vertigo, ataxia, dysarthria, convulsions.</p><p>&nbsp;</p><p><u>Not known</u>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Somnolence or insomnia, myoclonuis, seizures, peripheral neuropathy manifesting as&nbsp;&nbsp; paraesthesia, pain, furry sensation, and tingling in the extremities.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aseptic meningitis.</p><p>&nbsp;</p><p><em>Eye disorders</em></p><p><u>Very rare</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disturbance of vision, e.g. diplopia, myopia.</p><p><u>Not known</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oculogyric crisis, optic neuropathy/neuritis (isolated cases)</p><p>&nbsp;</p><p><em>Cardiac disorders</em></p><p><u>Rare</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ECG changes like flattening of T-wave</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Gastro-intestinal disorders</em></p><p><u>Not Known</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting, nausea, diarrhoea, glossitis and stomatitis, eructation with bitter taste, epigastric pressure, metallic taste, furred tongue.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dysphagia (caused by central nervous effects of metronidazole)</p><p>&nbsp;</p><p><em>Hepatobiliary disorders</em></p><p><u>Very rare</u>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abnormal values of hepatic enzymes and bilirubin</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis, jaundice, pancreatitis</p><p>&nbsp;</p><p><em>Skin and subcutaneous tissue disorders</em></p><p><u>Very rare</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic skin reactions, e. g. pruritus, urticaria, STEVENS-JOHNSON syndrome , toxic epidermal necrolysis</p><p><u>Not known</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythema multiforme</p><p>&nbsp;</p><p><em>Musculoskeletal and connective tissue disorders</em></p><p><u>Very rare</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arthralgia, myalgia</p><p>&nbsp;</p><p><em>Renal and urinary disorders</em></p><p><u>Uncommon</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dark coloured urine (due to a metabolite of metronidazole)</p><p>&nbsp;</p><p><em>General disorders and administration site conditions</em></p><p><u>Not known</u>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vein irritations (up to thrombophlebitis) after intravenous administration.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; States of weakness, fever</p><p>&nbsp;</p><p>Paediatric population</p><p>Frequency, type and severity of adverse reactions in children are the same as in adults.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Reporting of adverse reactions</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local requirements. </u></p><p><br />&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><ul><li>Saudi Arabia</li></ul><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance and Drug Safety Centre ( NPC )</p><ul><li>Fax: +966 11 205 7662</li><li>Call NPC at 00966 11 2038222, Ext 2317-2356-2340</li><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Symptoms</em></strong></p><p>As signs and symptoms of overdose the undesirable effects described under section 4.8 may appear. Single oral doses of metronidazole, up to 12g have been reported in suicide attempts and accidental overdoses. Symptoms were limited to vomiting, ataxia and slight disorientation.</p><p>&nbsp;</p><p><strong><em>Treatment</em></strong></p><p>There is no specific treatment or antidote that can be applied in the case of gross overdose of metronidazole. If required, metronidazole can be effectively eliminated by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmaco-therapeutic group: Anti-infectives for systemic use &ndash; imidazole derivatives</p><p>ATC Code: J01X D01</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Mechanism of action</em></p><p>Metronidazole itself is ineffective. It is a stable compound able to penetrate into microorganisms.</p><p>&nbsp;</p><p>Under anaerobic conditions nitroso radicals acting on DNA are formed from metronidazole by the microbial pyruvate-ferredoxin-oxidoreductase, with oxidation of ferredoxin and flavodoxin. Nitroso radicals form adducts with base pairs of the DNA, thus leading to breaking of the DNA chain and consecutively to cell death.</p><p>&nbsp;</p><p><em>PK/PD relationship</em></p><p>Metronidazole acts in a concentration dependent manner. The efficacy of metronidazole mainly depends on the quotient of the maximum serum concentration (cmax) and the minimum inhibitory concentration (MIC) relevant for the microorganism concerned.</p><p>&nbsp;</p><p><em>Breakpoints</em></p><p>For the testing of metronidazole usual dilution series are applied. The following minimum inhibitory concentration have been established to distinguish susceptible from resistant</p><p>microorganisms:</p><p>EUCAST <em>(European Committee on Antimicrobial Susceptibility Testing, Version 1.3, January 5, 2011) </em>breakpoints separating susceptible (S) from<em> </em>resistant organisms (R) are as follows:</p><p>Gram-positive anaerobes (S: &le; 4 mg/l R &gt; 4 mg/l)</p><p>Gram-negative anaerobes (S: &le; 4 mg/l R &gt; 4 mg/l)</p><p>&nbsp;</p><p>&nbsp;</p><p>List of susceptible and resistant organisms.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Commonly susceptible species</p></td></tr><tr><td style="vertical-align:top"><p><em>Anaerobes</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Bacteroides fragilis</em></p></td></tr><tr><td style="vertical-align:top"><p>Clostridium difficile&deg;</p></td></tr><tr><td style="vertical-align:top"><p>Clostridium perfringens&deg;&Delta;</p><p>&nbsp;</p><p>Eubacterium</p></td></tr><tr><td style="vertical-align:top"><p>Fusobacterium spp.&deg;</p></td></tr><tr><td style="vertical-align:top"><p>Peptoniphilus spp.&deg;</p></td></tr><tr><td style="vertical-align:top"><p>Peptostreptococcus spp.&deg;</p></td></tr><tr><td style="vertical-align:top"><p>Porphyromonas spp.&deg;</p></td></tr><tr><td style="vertical-align:top"><p>Prevotella spp.</p></td></tr><tr><td style="vertical-align:top"><p>Veillonella spp.&deg;</p></td></tr><tr><td style="vertical-align:top"><p>Other micro-organisms</p></td></tr><tr><td style="vertical-align:top"><p>Entamoeba histolytica&deg;</p></td></tr><tr><td style="vertical-align:top"><p>Gardnerella vaginalis&deg;</p></td></tr><tr><td style="vertical-align:top"><p>Giardia lamblia&deg;</p></td></tr><tr><td style="vertical-align:top"><p>Trichomonas vaginalis&deg;</p></td></tr><tr><td style="vertical-align:top"><p>Inherently resistant organisms</p></td></tr><tr><td style="vertical-align:top"><p>All obligate aerobes</p></td></tr><tr><td style="vertical-align:top"><p><em>Gram-positive micro-organisms</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Actinomyces spp.</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus </em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><em>Propionibacterium acnes</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus </em>spp<em>.</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus </em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><em>Gram-negative micro-organisms</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus </em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><em>Mobiluncus</em></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&deg; </strong>At the time of publication of these tables, no up-to-date data were available. In primary literature, standard reference books and therapy recommendations susceptibility of the respective strains is assumed.</p><p>&Delta; Only to be used in patients with allergy to penicillin</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>Mechanisms of resistance to metronidazole</em></strong></p><p>The mechanisms of metronidazole resistance are still understood only in part.</p><p>Strains of <em>Bacteroides </em>being resistant to metronidazole possess genes encoding nitroimidazole reductases converting nitroimidazoles to aminoimidazoles. Therefore the formation of the antibacterially effective nitroso radicals is inhibited.</p><p>&nbsp;</p><p>There is full cross resistance between metronidazole and the other nitroimidazole derivatives (tinidazole, ornidazole, nimorazole). The prevalence of acquired resistance of individual species may vary, depending on region and time. Therefore especially for the adequate treatment of severe infections specific local information regarding resistance should be available. If there is doubt about the efficacy of metronidazole due to the local resistance situation, expert advice should be sought. Especially in the case of severe infections or failure of treatment, microbiological diagnosis including determination of species of the microorganism and its susceptibility to metronidazole is required.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Absorption: </em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Metronidazole is readily absorbed from the gastrointestinal tract and the oral bioavailability is &gt; 90%. Consequently, the same mg dose will result in similar exposure (AUC) when switching between intravenous and oral dosing.</p><p>&nbsp;</p><p><strong><em>Distribution:</em></strong></p><p>Metronidazole is widely distributed in body tissues after injection. It also diffuses across the placenta, and is found in breast milk of nursing mothers in concentrations equivalent to those in serum. Protein binding is less than 20 %, the apparent volume of distribution is 36 litres.</p><p>&nbsp;</p><p><strong><em>Biotransformation:</em></strong></p><p>Metronidazole is metabolised in the liver by side-chain oxidation and glucuronide formation. Its metabolites include an acid oxidation product, a hydroxy derivative and glucuronide. The major metabolite in the serum is the hydroxylated metabolite, the major metabolite in the urine is the acid metabolite.</p><p>&nbsp;</p><p><strong><em>Elimination:</em></strong></p><p>Approximately 80% of the substance is excreted in urine with less than 10% in the form of the unchanged drug substance . Small quantities are excreted via the liver. Elimination half-life is 8 (6-10) hours.</p><p>&nbsp;</p><p><strong><em>Characteristics in special patient groups:</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Renal insufficiency delays excretion only to an unimportant degree. The elimination half-life of</p><p>metronidazole remains unchanged in the presence of renal failure, however such patients retain the metabolites of metronidazole. The clinical significance of this is not known at present.</p><p>Delayed plasma clearance and prolonged serum half-life (up to 30 h) is to be expected in severe liver disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Repeated dose toxicity</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Following repeated administration ataxia and tremor were observed in the dog and a dose-dependent increase in hepatocellular degeneration was observed in the monkey during a 12 month study.</p><p>&nbsp;</p><p><strong><em>Mutagenic and tumorigenic potential</em></strong></p><p>Metronidazole was mutagenic in bacteria after nitroreduction, however it was not mutagenic in mammalian cells in vitro and in vivo. In addition, DNA damage was not observed in the lymphocytes of patients treated with metronidazole.</p><p>&nbsp;</p><p>There is evidence to suggest that metronidazole is tumorigenic in the mouse and rat. There was an increase in the incidence of lung tumours in mice (after the oral administration of 3.1-fold the maximum recommended human dose of metronidazole of 1,500 mg/d), however, this does not seem to be due to a genotoxic mechanism as no changes in the mutation rates were observed in various organs of transgenic mice following high doses of metronidazole.</p><p>&nbsp;</p><p><strong><em>Reproduction toxicity</em></strong></p><p>No teratogenicity or embryotoxicity was observed in the rat or rabbit.</p><p>&nbsp;</p><p>Following repeated administration for 26-80 weeks to rats, testicular and prostatic dystrophy were observed at high doses (14.2 to 28.5-fold the maximum recommended human dose of metronidazole of 1,500 mg/d).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citric acid Monohydrate,</p><p>Anhydrous Disodium Hydrogen Phosphate,</p><p>Sodium Chloride</p><p>Water for Injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Metronidazole 5mg/ 1 ml after the expiry date which is stated on the Bag label after EXP:. The expiry date refers to the last day of that month.

Shelf life: 24 months. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&ordm;C.</p><p>Do not refrigerate.</p><p>Keep out of the sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions inside the plastic container also can leach out certain of its chemical components in very small amounts before the expiration period is attained. However, the safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p><p><strong>INSTRUCTIONS FOR USE</strong></p><p><strong>&nbsp;</strong></p><p><strong>To Open</strong></p><p>&nbsp;</p><p>Tear outer wrap at notch and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.</p><p>&nbsp;</p><p><strong>Preparation for Administration</strong></p><p><strong>&nbsp;</strong></p><p><strong>(Use aseptic technique)</strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close flow control clamp of administration set.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove cover from outlet port at bottom of container.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. <strong>NOTE</strong>: See full directions on administration set carton.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suspend container from hanger.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Squeeze and release drip chamber to establish proper fluid level in chamber.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open flow control clamp and clear air from set. Close clamp.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Regulate rate of administration with flow control clamp.</p><p>&nbsp;</p><p><strong>WARNING: Do not use flexible container in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is complete.</strong></p><p><strong>&nbsp;</strong></p><p><strong>HOW SUPPLIED</strong></p><p>Metronidazole 5 mg/ 1ml Injection, USP, sterile, is supplied in 100 mL single dose flexible containers, each containing 500 mg (5 mg/mL) of metronidazole (List 7811).</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>NDC No.</strong></p></td><td style="vertical-align:top"><p><strong>Product</strong></p></td><td style="vertical-align:top"><p><strong>Fill Volume/Container Size</strong></p></td></tr><tr><td style="vertical-align:top"><p>0409-7811-37</p></td><td style="vertical-align:top"><p>Metronidazole Injection, USP</p></td><td style="vertical-align:top"><p>100 mL</p></td></tr><tr><td style="vertical-align:top"><p>0409-7811-24</p></td><td style="vertical-align:top"><p>Metronidazole Injection, USP</p></td><td style="vertical-align:top"><p>100 mL</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Hospira Inc, 
Lake Forest, 
Chicago Illinois, 
United states

MANUFACUTRED BY

ICU medical Fleet Services LLC, 
3900 Howard Lane Austin 
TX 78728, AUSTIN, 
United states

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2017 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>